Stay tuned on the latest company news and upcoming events

APRIL 06, 2021
Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

JUNE 10, 2020
Azafaros expands executive management team and operations

FEBRUARY 06, 2020
Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

JULY 23, 2018
Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders

National Tay-Sachs & Allied Diseases Association, 22-25th April, 2021
2021 Annual Family Conference
https://ntsad.org/index.php/2021-annual-family-conference

ICIEM, 21-23rd November, 2021
Virtual Meeting
https://iciem2021.com.au/